The outcomes of this study could serve as key complementary information to health systems and policy-makers to implement a patient-centered framework for public health decision-making that includes a comprehensive analysis of the value and impact of novel hemophilia therapies such as EHL FVIII products, which have the potential to decrease the treatment burden and improve adherence, resulting in better health outcomes. This evidence concerns the gene F8 and hemophilia.